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Four phloroglucinol derivatives, named mallotophcnone (5-methylene-bis-t,6-dihydroxy-3-methyl-4-methoxyacetophenone), mallotochromene (S- 
acetyl-§,7-dihyd~oxy-6-(3-acetyl-2,4-dihydroxy-S-methyl-6-methoxybenzyl)-2,2-dimethylchromene), mallotojaponin (3-(3,3(dimethylallyl)§-(3(ace- 
tyl-2,4-dihydroxy-5-methyI-6-methoxybenzyl)-phloracetophenone) a d mallotolerin (3-(3-methyl-2-hydroxybut-3-enyl)-S-(3-acetyl-2,4-dihy~~ox~ 
S-methyl-6-methoxybenzyl).phloracetophenone), have been tested for their ability to inhibit the activity of human immunodeficieacy virus (HIV)- 
reverse transcriptase. Under the reaction conditions with (rA),.(dT),,_,, as the template. primer, the enzyme activity was inhibited by appeoximately 
70% in the peesence of IO &ml mallotochromene or mallotojaponin, whereas mallotophenone and mallotoierin were much less inhibitory to the 
enzyme. The enzyme activity was also inhibited, though to lesser extent, by these compounds under similar conditions with initiated MS-2 phage 
RNA as the template*primer. The mode of inhibition was, as analyzed with mallotojaponin, competivite with respect to the template.primer, 
@A),, (dT),,-,,, and non-competitive with respect o the triphosphate substrate, dTTP. The #i value of mallotojaponin for HIV-reverse transcriptase 
was determined to be 6.1 HIM. 
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1. INTRODUCTION tion, since they are known to be non-toxic by a long 
The recent search for new antiretrovirals for treat- 
ment of acquired immunodeficiency syndrome (AIDS) 
has been directed mainly to well-characterized com- 
pounds such as nucleoside analogues with an expected 
mode of action. These chemically synthesized com- 
pounds have, however, revealed various side effects 
when administered to patients with AIDS or AIDS- 
related complex (ARC); e.g. anemia and leucopenia for 
3 ’ -azido-3 ’ -deoxythymidine (AZT) [l] and peripheral 
neuropathy for 2’,3’-dideoxycytidine (DDC) 121 and 
2’,3’-dideoxyinosine (DDI) [3,4]. 
Some traditional medicines, mainly composed of 
plant extracts, have therefore attracted special atten- 
practical experience [5] and they may contain yet 
unknown new compounds with antiviral activity. In 
search for inhibitor(s) of human immunodeficiency 
virus (HIV)-reverse transcriptase, it was found that a 
Kampo drug, Sho-saiko-to, was inhibitory not only to 
this enzyme activity [6], but also to HIV replication in 
lymphocyte cultures of HIV-seropositive asymptomatic 
and ARC subjects [7]. An active component of Sho- 
saiko-to has been identified as 5,6,7-trihydroxyflavone 
(baicalein) which strongly inhibits HIV-reverse 
transcriptase activity [S], Besides baicalein, some other 
flavonoids were shown to be potent inhibitors of HIV- 
reverse transcriptase [9]. 
In an extensive survey of plant extracts, we found 
that two new phloroglucinol derivatives, malloto- 
japonin and mallotochromene, isolated from the 
pericarps of Malfotus japonicus had strong anti-reverse 
transcriptase activity, This paper describes this finding 
together with their action mechanism. 
Abbreviurions: AIDS, acquired immunodeficiency syndrome; ARC, 
AIDS-related complex; HIV, human immunodeficiency virus; 
baicalein, S&,7-trihydroxyflavonc; mallotophenone, S-mcthylene- 
Dis-2,6-dihydroxy-3-~nettiyi~4-melhoxyacetop~~eno~~e; lllallolo- 
chrotnene, 8-acetyl-S,7-dillydroxy-6-(3.ace~yl-2,4-di~~ydroxy.5- 
methyl-G-methoxybenzyl).2,2-ditnethylchromcnc; mallotojaponin, 
3~(3,3-dimetl~ylallyI)-5-(3-acetyl-2,4~di~~ydroxy-5-mcthyl-6-tnct~~oxy- 
berzyl).plttoracetophenonc; mallotolerin, 3-(3-metliyl-2-hydroxy- 
but-3-eayl)-5-(3-acctyl~2,4-dihydroxy-S-~~~ct~iyl-6-methoxybenzyl)- 
plilorece~o~~l~c~io~Ic 
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2. MATERIALS AND METHODS 
S~Methylene-his-2,6-dihydroxy-3~~netl~yi~4-t~~ct~~~xy~~etop~~ettat~c 
(mnlletopl~etionc) ttttd its three il~iulogucs (mellntochromrttc, 
n~nllotolcrin atid n~allotnjrrponin) wcrc isolated and purified frown the 
pericatps of ivfal/o/rrs jqwrlnrs Muell. Ary. (Euphorbiaceae) us 
described previously [l&12), Structural formulnc of these COW 
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pounds are shown in Fig. 1. MS-2 phage RNA was obtained from 
Boehringer, Mannheim, Germany. A primer DNA (18-mer; 5’- 
CTTCTTTGTTGTCTTCGA-3’). hybridizable with MS-2 RNA at 39 
to 56 bases downstream of the coat protein gene, was chemically syn- 
thesized by a DNA synthesizer (ABI Co., USA). This oligonucleotide 
was mixed with MS-2 RNA at a molar ratio of I : 20 and annealed to 
make initiated MS-2 RNA as described previously [13]. The sources 
of other materials used in this work were as follows: [3H]dTTP from 
Amersham International (Amersham, UK); unlabeled dTTP, po- 
ly(rA), oligo(dT) from P-L Biochemicals (Milwaukee, WI, USA); and 
DEAE-cellulose paper disc (DE81, diameter 23 mm) from Whatman 
(Springfield Mill, Maidstone, UK). 
2.2. HIV-reverse transcriptase 
HIV-l reverse transcriptase was purified from E. co/i harboring an 
expression plasmid for the precise coding sequence of the enzyme. 
Details of the purification procedures of p66 enzyme protein and 
some of its properties will appear elsewhere [14]. The purified enzyme 
was a generous gift from Dr. S.H. Wilson, NIH, USA. 
2.3. Assay for reverse transcriptase 
Rcversd -transcriptase actiiity was measured with each of 
@A), . (dT)l2-18 (reaction mixture A) and initiated MS-2 phage RNA 
(reaction mixture B) as the template ‘primer under the optimized 
reaction conditions for the respective template + primers. The reaction 
mixture A contained the following components: 50 mM Tris-HCI, pH 
8.0; 3 pg/ml (rA)” * (dT)12_18 (base ratio, 2: I); 10&M [3H]dTTP 
(400 cpm/pmol); 5 mM dithiothreitol; 50 mM KCI; 15% (v/v) 
glycerol; and 5 mM MgC12. The reaction mixture I3 included the 
following: 50 mM Tris-HCI, pH 7.5; 10 pg/ml initiated MS-2 RNA; 
5 mM dithiothreitol; 2 mM MgC12; 1 pM each af dATP, dCTP, 
dGTP and [3H]dTTP (6000 cpm/pmol); and 15% (v/v) glycerol. All 
incubations (50~1) were carried out at 37°C for 30 min, and the reac- 
tion was stopped by adding 20~1 of 0.2 M EDTA and immersing the 
mixture in ice. Then, 50~1 of the mixture was transferred to a DE81 
filter paper disc and processed for radioactivity counting as previous- 
ly described [IS]. 
3. RESULTS 
3.1. Effects of various phloroglucinol derivatives on 
the activity of HIV-reverse transcriptase 
Effects of mallotophenone and its analogues on the 
activity of HIV-reverse transcriptase were examined 
under the reaction conditions described in section 2. As 
shown in Fig. 2A, the enzyme activity was inhibited by 
26, 38, 67 and 75% in the presence of lOpg/ml 
mallotophenon.e, mallotolerin, mallotojaponin and 
mallotochromene, respectively, with (rA)” - (dT)lz- I8 as 
the template-primer, The degree of inhibition was 
dose-dependent and more than 90% inhibition was 
achieved by mallotoj3ponin, for example, at a concen- 
tration of 25 pg/ml, The degrees of inhibition by 
mallotojaponin and mallotochromene are much 
stronger than those by mallotophenone and 
mallotolerin, The enzyme activity was also inhibited, 
though to lesser extent, by these compounds in the 
presence of initiated MS-2 phage RNA as the 
template - primer (Fig, 2B). 
3.2. Analysis of the mode of inhibition by malloto- 
japonin and determination of inhibition constant 
The mode of’ inhibition of reverse transcriptase ac- 
tivity by mallotojaponin was analyzed by changing the 
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Fig. 1. Structural formulae of the four phloroglucinol derivatives 
examined in this study. A, mallotojaponin; R, mallotolerin; C, 
mallotochromene; and D, mallotophenone. 
concentrations of either the template qprimer, 
(rA)” .(dT),z- 18, or the triphosphate substrate, dTTP, 
in the presence of various concentrations of the in- 
hibitor, mallotojaponin. As shown in Fig. 3, malloto- 
japonin inhibited the enzyme activity competitively 
with respect to the template. primer, @A),, - (dT)I2- 18, 
and non-competitively with respect to the triphosphate 
substrate, dTTP. The Ki value of the enzyme for 
lnhlbllor concenlralion~glml) 
Fig. 2. Effects of four phloroglucinol derivalivcs on the activity of 
HIV-I reverse transcriptase. Reverse trenscriptasc activity was 
measured with each of (rA),, *(dT)t~-l~ (A) and initiated MS-2 phage 
RNA (U) under the conditions described in section 2 in the presence 
of various conccnlralionx of each of Ihe four phlorogluclnol 
derivatives as indicated in the figure, by determining the 
incorporation of [%]dTMP. s’hc compounds tested and the symbols 
used are: ti~allotojaponin (Q, mallotolcrin (o), t11ailotochr01~1c~~c 
(A), and mallotopherloflc (A). The lOOI values wcrc 5,s (A) and 2,7 
(U) pmol. 
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Fig. 3. Analysis of the mode of inhibition of HIV-l reverse 
transcriptase activity by mallotojaponin. Reactions were carried out 
under the conditions described in section 2, except that various 
concentrations of @A), * (dT)lz-is (A) and [3H]dTTP (B) were used as 
the template * primer and the triphosphate substrate, respectively, in 
the presence of various concentrations of mallotojaponin. 
Mallotojaponin concentrations were 0 (O), 5 (c), 8 (A), and 12 (A) 
mallotojaponin was determined to be 6.1 ,uM by replot- 
ting (Dixon plot) the data of Fig. 3A. 
4. DISCUSSION 
Four phloroglucinol derivatives examined in the pre- 
sent study have been isolated from pericarps of 
Ma/lotus japonicus which is a deciduous tree with red 
colored buds and is widely distributed in Japan 
[IO-121. Some parts of tree have already been used for 
a long time in folk medicine; the bark for treatment of 
ulcers and cancer, the leaves for boils. It was shown in 
previous reports [lo-121 that these compounds are 
more or less cytotoxic to KB and L 5 178Y cells in 
culture as well as to Ehrlich carcinoma, ascites and solid 
forms, in mice. To know the underlying mechanism(s) 
of the cytotoxicity, the effects of these compounds on 
various DNA polymerases have been tested and 
mallotojaponin was found to be a selective inhibitor of 
DNA polymerase’ fl purified from KB cells (Nakane, et 
al., manuscript in preparation). 
An extensive study has revealed that, of the four 
compounds tested, mallotojaponin and malloto- 
chromene are particularly strong inhibitors for HIV- 
reverse transcriptase (Fig. 2). Differences in the inhibi- 
tion potential among the four compounds seem to be 
due to the presence or absence and the nature of the side 
chains introduced (Fig. 1). The mode of inhibition of 
the enzyme activity by mallotojaponin was competitive 
with respect to the template a primer, (rA),, B (dT)lz- 18, 
and non-competitive with respect to the triphosphate 
substrate, dTTP (Fig. 3). This type of inhibition is 
similar to those of suramin [16], baicalein [8] and other 
flavonoids [9], catcchin derivatives [17] and asterri- 
quinone and its analogues [18], indicating that all these 
cyclic compounds have the same inhibition mechanism 
for HIV-reverse transcriptase; i,e. the inhibitors in- 
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terfere with the template. primer binding to the enzyme 
molecule. The inhibition was also observed when ex- 
amined with initiated MS-2 phage RNA as a natural 
template. primer, ind.icating that the observed inhibi- 
tion is not specific for the synthetic template - primer, 
WA. @lb-Is. 
Although mallotojaponin and mallotochromene are 
potent inhibitors of HIV-reverse transcriptase as 
described here, it is not yet clear whether these two com- 
pounds are effective as anti-HIV agents. It totally 
depends on whether and to what extent they inhibit HIV 
replication in intact cell culture system with susceptible 
human lymphocytes. Such tests are now in progress in 
our laboratories. 
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